Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851597 | 0.71 | — | — | |
| SCHEMBL5365900 | 0.64 | TAAR1 (0.49) | — | |
| SCHEMBL2971945 | 0.64 | KDM4E (0.35) | — | |
| SCHEMBL207490 | 0.64 | AHR (0.42) | GPR84 | |
| SCHEMBL9739128 | 0.62 | — | — | |
| SCHEMBL6017271 | 0.61 | AR (0.32) | — | |
| SCHEMBL2441098 | 0.60 | GPR84 (0.31) | GPR84 | |
| SCHEMBL1923230 | 0.60 | HTR1D (0.39) | — | |
| SCHEMBL17423817 | 0.60 | — | — | |
| SCHEMBL4502393 | 0.59 | KDM4E (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-116368146-A | Novel ligands for asialoglycoprotein receptors | 赛诺菲 | 2023-06-30 | — | — | CN | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11390621-B2 | Chiral indole compounds and their use | ARIAGEN, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-20210179604-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2020214740-A9 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200354353-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020214740-A1 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3713937-A2 | INDOLE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS | Ariagen, Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
| CN-111587249-A | Indole compounds and uses thereof | 阿里根公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-105315259-B | Pyridine amine pyrimidine derivates, its preparation method and application | 上海艾力斯医药科技有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179604-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | GPR84 801/4885 |
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | GPR84 801/4885 |
| US-20200354353-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | GPR84 801/4885 |
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | GPR84 801/4885 |
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | IDO1, IDO2, INMT | GPR84 300/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | GPR84 3883/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | GPR84 73/4885 |
| US-11390621-B2 | Chiral indole compounds and their use | IDO1, IDO2, INMT | GPR84 300/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | GPR84 801/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | GPR84 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.